Summary
A sample labeled as Proviron (Mesterolone) was analyzed by Janoshik Analytical to verify its composition and potency. The sample, identified by Task Number #51116, was submitted by Asteroidbiotech and manufactured by the same entity.
The analysis confirmed the presence of Mesterolone with measured dosages ranging from 25.81 mg to 28.43 mg per unit.
The testing was ordered on 9 October 2024, with the sample received on 21 October 2024 and the final analysis conducted on 23 October 2024.
Detailed Report
Product Overview
- Manufacturer: Asteroidbiotech
- Product Name: Proviron
- Active Ingredient: Mesterolone
- Batch Number: Oct/24
- Expiration Date: Not provided
- Delivery Method: Assumed oral tablet
Testing Details
- Task Number: #51116
- Testing Ordered: 9 October 2024
- Sample Received: 21 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Asteroidbiotech (manufacturer)
- Analysis Paid For By: Asteroidbiotech (manufacturer)
Testing Results
- Detected Compound: Mesterolone
- Measured Dosages:
- 27.07 mg
- 28.43 mg
- 27.05 mg
- 25.81 mg
- Accuracy: Slight variability observed in dosage
Verification Details
Verification URL: https://janoshik.com/tests/51116_A1CMS7AFY5GT
Evaluation of Manufacturer-Submitted Testing
The analysis confirmed that the Proviron sample contains Mesterolone within a range of 25.81 mg to 28.43 mg per unit, suggesting slight variations in dosage.
Proviron (Mesterolone) is an androgenic steroid commonly used in hormone replacement therapy and bodybuilding to increase free testosterone levels and reduce estrogenic side effects.
While the dosage range is relatively consistent, the observed variations might indicate minor inconsistencies in manufacturing. Users should exercise caution and consider independent testing across multiple batches to ensure uniform quality.
Conclusion
The analysis confirms that the Proviron sample contains Mesterolone, with dosages ranging from 25.81 mg to 28.43 mg per unit. While the results suggest relative accuracy, slight dosage inconsistencies indicate potential manufacturing variability.
This report is provided for educational and harm reduction purposes, ensuring consumers make informed decisions about pharmaceutical products.
Disclaimer
This report is published for informational and harm reduction purposes. The analysis was conducted on a single sample, and results may not reflect the consistency of future batches. Readers are encouraged to use this information responsibly.
